Adjuvant Osimertinib and Advanced EGFR-Mutated NSCLC | NEJM
Автор: NEJM Group
Загружено: 2024-08-15
Просмотров: 1667
Описание:
Patients with unresectable stage III EGFR-mutated non–small-cell lung cancer have no approved targeted treatments available.
Research findings on adjuvant osimertinib are summarized in a new Quick Take video.
To see the full article, follow this link: https://nej.md/451OXwi
#oncology #pulmonology #criticalcare #clinicaltrials #nejm
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: